SNCA and Parkinson disease: Compounds such as epoxomicin, PSI, lactacystin (MG132), and SUMO1-15–55 demonstrate the ability to inhibit the proteasome system, leading to a reduction in alpha-synuclein levels and mitigating dopaminergic degeneration in PD (Inden et al. 2005; Sun et al. 2007; Rott et al. 2017a, b).